NDAORALTABLETPriority Review
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Mechanism of Action
Rifapentine, a cyclopentyl rifamycin, is an antimycobacterial agent [see ] .
Pharmacologic Class:
Rifamycin Antimycobacterial
Clinical Trials (5)
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
Started Feb 2024
30 enrolled
HIV-associated Tuberculosis
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Started May 2021
0TuberculosisHiv
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
Started Feb 2021
37 enrolled
HIV InfectionLTBI
Doravirine, Rifapentine and Isoniazid Interaction
Started Apr 2019
11 enrolled
Latent TuberculosisHuman Immunodeficiency VirusRifamycins Causing Adverse Effects in Therapeutic Use+1 more
Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
Started Dec 2012
25 enrolled
Tuberculosis